Drug Profile

Influenza A virus vaccine H5N1 - GC Biopharma/Mogam Biotechnology Research Institute

Alternative Names: MG 1109

Latest Information Update: 01 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Green Cross
Developer GC Biopharma
Class Influenza A virus H5N1 vaccines; Vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Influenza A virus H5N1 subtype

Most Recent Events

29 Mar 2022 GC Pharma is now called GC Biopharma
15 Feb 2016 MG 1109 is still in development for Influenza-A virus H5N1 subtype (prevention) in South Korea
01 Mar 2014 Green Cross Corporation completes a phase III trial in Influenza-A virus H5N1 subtype (prevention) in South Korea (NCT01987011)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com